27% of U.S. broadband households own a connected device

Laura Pedulli | | Health Exec | Precision Medicine

Just over one-quarter of U.S. broadband households currently own and use at least one connected health device, according to research firm Parks Associates.

The survey of more than 5,000 U.S. broadband households also found that 13 percent indicated that they are very likely to purchase a connected health device during the next year.

“The most popular connected health devices are treadmills, exercise bikes and ellipticals,” said Harry Wang, director of health & mobile product research at Parks Associates. “These devices come with built-in support for mobile health apps, which effectively merges the demands of mobile and healthcare consumers."

The wearables market also is growing increasingly competitive, Wang said, citing Apple’s scheduled launch of iWatch that competes against larger brands like Motorola, Samsung and LG.

“To be successful in connected health, all form factors will need to leverage mobile connections in order to keep users engaged,” Wang said in a statement.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.